Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms
VR

VRTX

Market Closed

Vertex Pharmaceuticals Incorporated

NASDAQHealthcareBiotechnology
US
6.40K employees
CEO: Reshma Kewalramani
Founded: 1991
$538.60
+$0.00(+NaN%)
Market Cap
136.56B
Beta
0.32
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Vertex trades 24.9% above its high-confidence fair value estimate of $404.31, indicating potential overvaluation with significant downside risk as 85.7% of Monte Carlo scenarios fall below the current price. Despite excellent financial health and profitability, valuation dispersion and high volatility (107.86% coefficient of variation) highlight substantial uncertainty. The combination of strong fundamentals and high price premium signals elevated investment risk.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore VRTX

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

VRTX in the Healthcare

Large Cap
Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →